|
See related Replagal inj[利甫蓋素 注射劑] information |
|
|
|
製造商 |
Shire |
|
代理/經銷商 |
Excelsior |
|
成份 |
α-galactosidase A |
|
適應症 |
Long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry disease (α-galactosidase A deficiency). |
|
用量 |
0.2 mg/kg body weight every other weeks by IV infusion over 40 mins. |
|
過量 |
View Replagal[利甫蓋素] overdosage for action to be taken in the event of an overdose. |
|
美國食品藥物管理局之懷孕等級 |
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are no controlled studies in pregnant women or animal-reproduction studies have shown an adverse effect (other than a decrease in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is no evidence of a risk in later trimesters). |
|
禁忌 |
[Click for Replagal[利甫蓋素] detailed prescribing infomation] |
|
注意事項 |
Hypersensitivity reactions. |
|
不良反應 |
Headache, flushing, nausea, rigors, infusion related reactions, pyrexia, chest tightness.
View ADR Monitoring Website[參閱藥物不良反應監測表格] |
|
交互作用 |
Avoid co-administration with chloroquine, amiodarone, benoquin or gentamicin.
View more drug interactions with Replagal[利甫蓋素] |
|
使用上注意 |
For caution against possible variation of physical aspect of medicine... click to view Replagal[利甫蓋素] detailed prescribing infomation |
|
儲存 |
View Replagal[利甫蓋素] storage conditions for details to ensure optimal shelf-life. |
|
描述 |
View Replagal[利甫蓋素] description for details of the chemical structure and excipients (inactive components). |
|
作用 |
View Replagal[利甫蓋素] mechanism of action for pharmacodynamics and pharmacokinetics details. |
|
本商品之市售規格 |
|
劑型 |
包裝 |
圖片 |
|
Replagal 注射劑 |
|
Replagal 1 mg/1 mL x 3.5 mL x 1's |
|
|
|
Manufacturer: |
Shire |
|
Distributor: |
Excelsior
|
|
|
|
